EGFR and non-small cell lung carcinoma: Finally, the phase II RAIN study (NCT03805841) is evaluating the role of tarloxotinib (TH-4000), a hypoxia-activated prodrug that releases an irreversible pan-HER TKI, in NSCLC patients harboring EGFR or HER2 exon 20 insertions.